10 Recent Oncology Drug Approvals

Slideshow

This slideshow summarizes recent US Food and Drug Administration approvals of new oncology drugs and oncology drug indications.

With rapid advancements in the field of oncology come frequent US Food and Drug Administration (FDA) approvals of new oncology drugs, as well as updates to the indications and warnings of existing therapies. In 2018, 17 of 59 new drug approvals (29%) were oncology-related, and the trend seems to continue so far in 2019. This slideshow highlights several newly approved oncology drugs or those with new indications in 2018 and the first quarter of 2019.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Related Content
27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
June 19th 2025
Article
PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.

BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia

Roman Fabbricatore
June 19th 2025
Article

BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

Tim Cortese
June 19th 2025
Article

First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management

Russ Conroy
June 18th 2025
Article

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.